ADVA
12.1.2021 09:02:30 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced the expansion of its Ensemble Harmony Ecosystem to include disaggregated packet networking. Alpha Networks, Delta, Edgecore Networks and UfiSpace have all joined the open multi-vendor program. Each new member offers high-performance hardware platforms proven to interoperate with ADVA’s Ensemble Activator, a carrier-grade network operating system (NOS) specifically designed for white box switches. The Ensemble Harmony Ecosystem helps to accelerate softwarization and virtualization by offering service providers and enterprises access to the industry’s most comprehensive portfolio of flexible and disaggregated networking technologies. The addition of white box switch suppliers means it now delivers even more value to customers and helps to further simplify their transition to software-driven networking.
“Since the inception of NFV, our Ensemble Harmony Ecosystem has led the way, delivering unparalleled variety and choice of onboarded virtual network functions (VNFs). Now we’re opening up this unique multi-vendor environment to include some of the industry’s most innovative hardware suppliers, ensuring easy interoperability and new levels of collaboration for the rapid development of future services,” said James Buchanan, GM, Edge Cloud, ADVA. “This latest expansion of Ensemble Harmony will help more customers to realize the true value of virtualization and disaggregated packet networking as a catalyst to openness, componentized systems and innovation at the speed of software. The journey to white box switches and servers and software-driven networking is now simpler and more cost-efficient than ever before. ADVA is now the clear leader in network operating systems for white boxes.”
With the addition of leading hardware suppliers, ADVA’s open Ensemble Harmony Ecosystem provides everything service providers and businesses require to harness the power of disaggregated networking. Each of the new member companies offers highly efficient white box technology proven to interoperate successfully with ADVA’s Ensemble Activator , the first NOS designed for bare-metal switches. Already successful in trials with multiple global mobile network operators, including Telefónica and Vodafone, Ensemble Activator is the market’s most versatile operating system for disaggregated cell site gateways. When combined with Ensemble Harmony partner hardware, it offers new levels of agility and freedom and a clear route to cost-effective mass rollout of 5G services over large, geographically dispersed, multi-vendor networks.
“We’re excited to be among the first hardware partners to be welcomed into the Ensemble Harmony Ecosystem. It’s a community that shares our dedication to openness and interoperability. Together we can remove even more of the shackles of single-vendor proprietary solutions,” commented George Tchaparian, CEO, Edgecore Networks. “Today’s customers refuse to accept the constraints, the complexity and the expense of closed hardware and software systems. They demand the freedom to build scalable, cost-effective infrastructure on best-in-class open products and solutions. That’s why we’re working closely with Ensemble Harmony software partners, helping operators make the leap to virtualization and harness the benefits of openness and disaggregation.”
“ADVA’s Ensemble Harmony Ecosystem is a pillar of the open environment. Its philosophy is perfectly aligned with our own focus on disaggregation and open networking. What’s more, by collaborating with ADVA, we can add more value to our innovations and increase speed to market for our customers,” said Vincent Ho, CEO, UfiSpace. “We’ve been driving the next generation of open networking solutions with our carrier-grade disaggregated white box and network cloud solutions. Now, as part of Ensemble Harmony, we can give even more customers the freedom to choose from a wide range of fully integrated software and hardware technologies and select the ideal disaggregated solution for their business needs.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005057/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom